PHARMACEUTICAL COMBINATIONS OF HCV-PROTEASE AND -IRES INHIBITORS.

摘要

Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of: (a) at least one HCV IRES inhibitor; and (b) at least one HCV protease inhibitor; and optionally (c) at least one other therapeutic agent; for concurrent or consecutive administration in treating or ameliorating one or more symptoms of HCV, or disorders associated with HCV in a subject in need thereof.